Patients with AMD can successfully self-operate OCT device at home
SAN FRANCISCO — Patients with age-related macular degeneration could successfully self-operate an optical coherence tomography device at home, according to study findings presented at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.
“I would like to discuss with you a device that may truly change healthy management of patients with vascular diseases, including wet AMD,” Judy E. Kim, MD, professor of ophthalmology at Medical College of Wisconsin and OSN Retina/Vitreous Board Member, said.
Kim and colleagues conducted a prospective clinical trial comparing a patient-operated Notal OCT V2.5 device to a commercial in-office OCT device in consecutive eyes with dry and wet AMD and visual acuity of 20/400 or better to determine the usability and performance of a home OCT system.
Non-dilated patients were imaged by a commercial OCT, according to the presentation. After a 2-minute video tutorial, they self-operated the Notal OCT to capture images of their own eyes. Researchers compared images from the home OCT to the commercial OCT to determine the presence of intra- and/or subretinal fluid in the center 10 degrees of the macula.
Of 196 patients, 90% could successfully self-operate that home OCT and capture gradable images in at least one eye. Patient questionnaires also demonstrated that the patients’ experience was consistently positive regarding ability to use the video tutorial and the machine.
Kim reported that the Notal OCT device had comparable imaging to the commercial OCT device. Compared with the commercial office OCT, researchers found that fluid detection with Notal OCT had a sensitivity of 91.9% and specificity of 97%.
“Home OCT provides us an opportunity to personalize AMD management because we may be able to catch recurrence or progression as soon as it occurs and it may also provide the patient and the doctor with unique interim visit disease knowledge,” Kim said. “It may address the problem of undertreatment as well as treatment burden. It may also allow us to maintain the visual acuity of our patients over the course of the treatment.” – by Savannah Demko
Reference: Kim JE. Home OCT monitoring: The future of AMD management. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.
Disclosures: Kim reports consulting for Allergan, Cellcure, Clearside, Eyepoint, Genentech, Kodiak and Notal Vision; grant support from Notal Vision Inc. and Optos Inc.; and lecture fees from Novartis.